Sentence examples for incidence structure from inspiring English sources
An incidence structure automorphism preserving and reflecting the neighbor relation is called a collineation of Π.
Consider an incidence structure whose points are the points of a PGn(n+2,q) and whose block are the subspaces of codimension two, where n⩾2.
A failed symmetric design is a symmetric incidence structure in which any two points are joined by exactly one or λ blocks, and dually.
Consider an incidence structure whose points are the points of a PGn(n + 2,q) and whose block are the subspaces of codimension two, where n ≥ 2. Since every two subspaces of codimension two intersect in a subspace of codimension three or codimension four, it is easily seen that this incidence structure is a quasi-symmetric design.
Proof (i) For any d ∈ 〈 l 〉, φ ( d ) = d ∗ is a line of K ∗ which is the projective plane of order r where φ : K → K ∗ is the incidence structure epimorphism given in (PK3).
PK3: There is a projective plane Π ∗ and an incidence structure epimorphism χ : Π → Π ∗ such that P ∼ Q ⇔ χ ( P ) = χ ( Q ) and l ∼ m ⇔ χ ( l ) = χ ( m ).
In this paper incidence structures are defined as in [6] and blocks are called lines.
This paper examines some of the properties of point-weight incidence structures, i.e. incidence structures for which every point is assigned a positive integer weight.
One way to attack the problem of classifying incidence structures is via the action of their automorphism groups, which permits the use of heavy group theory machinery.
35– 37 Recent studies have shown that there is greater variation than believed in the incidence and structure of the Plasmodium falciparum histidine-rich protein, which is the target of many RDTs, and might account for some of this variability.
BRCA1 and BRCA2 mutations did not show different incidence between limited structure and adequate structure according to family structure in early onset patients (Table 5).> Overall 43 mutations (18 BRCA1 genes and 25 BRCA2 genes) were identified in high-risk breast cancer patients without a family history of breast or ovarian cancer.
